Medtronic, IBM Unveil SugarWise Diabetes App
Now in its final stage of development, the cognitive app being developed by Medtronic and IBM Watson Health was revealed at the American Diabetes Association’s 76th Scientific Sessions this week. Called SugarWise, the app is designed to reveal a diabetic’s patterns and trends related insulin levels, continuous glucose monitoring and nutritional data to help users make the connection between their behavior and their glucose levels, all in real time. According to an IBM release, the companies also released results from a hypoglycemia prediction data study of 10,000 patients that showed preliminary prediction accuracy of 75-86% within a two-to-four-hour window.
MedTech Intelligence reported on the app concept when it was announced by Medtronic and IBM at the Consumer Electronics Show in January. Read our interview with Medtronic’s Annette Brüls, president of Diabetes Service and Solutions, and what she had to say about the app: Coming Soon: Medtronic-IBM Watson App to Empower Diabetes Patients
Related Articles
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
-
An analysis of the HVAD pump implant kit showed moisture had entered the center post of the pump causing corrosion and demagnetization of the internal magnets, which may cause the pump to rotate incorrectly.
-
The catheter is part of the company’s transcatheter pulmonary valve system.
-
“This cutting-edge technology empowers us with the ability to navigate complex vascular procedures with greater precision, ensuring optimal outcomes for our patients. We are honored to be a part of this innovative program.”
